Neurogene Inc. Research and Development Expense
Neurogene Inc. (NGNE) reported Research and Development Expense of $25.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Neurogene Inc. research and development expense for the quarter ending 2026-06-30 was $25.47M, a 31.51% increase year-over-year.
- Neurogene Inc. research and development expense for the quarter ending 2026-03-31 was $25.15M, a 41.61% increase year-over-year.
- Neurogene Inc. research and development expense for the quarter ending 2025-12-31 was $20.64M, a 34.48% increase year-over-year.
- Neurogene Inc. research and development expense for the quarter ending 2025-09-30 was $17.24M, a 5.87% increase year-over-year.
- Neurogene Inc. research and development expense for fiscal 2025 was $75.01M, a 23.14% increase from fiscal 2024.
- Neurogene Inc. research and development expense for fiscal 2024 was $60.92M, a 37.22% increase from fiscal 2023.
- Neurogene Inc. research and development expense for fiscal 2023 was $44.39M, a 6.55% decline from fiscal 2022.
- Neurogene Inc. research and development expense for fiscal 2022 was $47.51M, a 21.30% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.47M 10-Q · filed 2026-08-11 | $50.62M 10-Q · filed 2026-08-11 | $71.26M derived: sum of 3 quarters · filed 2026-08-11 | $88.50M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2026-03-31 | $25.15M 10-Q · filed 2026-05-12 | $45.79M derived: sum of 2 quarters · filed 2026-05-12 | $63.03M derived: sum of 3 quarters · filed 2026-05-12 | $82.40M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-12-31 | $20.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $37.88M derived: sum of 2 quarters · filed 2026-03-24 | $57.25M derived: sum of 3 quarters · filed 2026-08-11 | $75.01M 10-K · filed 2026-03-24 | |||||
| 2025-09-30 | $17.24M 10-Q · filed 2025-11-13 | $36.61M derived: sum of 2 quarters · filed 2026-08-11 | $54.37M 10-Q · filed 2025-11-13 | $69.71M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | $19.37M 10-Q · filed 2026-08-11 | $37.13M 10-Q · filed 2026-08-11 | $52.47M derived: sum of 3 quarters · filed 2026-08-11 | $68.76M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-03-31 | $17.76M 10-Q · filed 2026-05-12 | $33.11M derived: sum of 2 quarters · filed 2026-05-12 | $49.39M derived: sum of 3 quarters · filed 2026-05-12 | $65.14M derived: sum of 4 quarters · filed 2026-05-12 | |||||
| 2024-12-31 | $15.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $31.63M derived: sum of 2 quarters · filed 2026-03-24 | $47.38M derived: sum of 3 quarters · filed 2026-03-24 | $60.92M 10-K · filed 2026-03-24 | |||||
| 2024-09-30 | $16.29M 10-Q · filed 2025-11-13 | $32.03M derived: sum of 2 quarters · filed 2025-11-13 | $45.57M 10-Q · filed 2025-11-13 | $57.75M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $15.74M 10-Q · filed 2025-08-11 | $29.29M 10-Q · filed 2025-08-11 | $41.47M derived: sum of 3 quarters · filed 2025-08-11 | $53.08M derived: sum of 4 quarters · filed 2025-08-11 | |||||
| 2024-03-31 | $13.54M 10-Q · filed 2025-05-09 | $25.73M derived: sum of 2 quarters · filed 2025-05-09 | $37.33M derived: sum of 3 quarters · filed 2025-05-09 | $47.65M derived: sum of 4 quarters · filed 2025-05-09 | |||||
| 2023-12-31 | $12.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $23.79M derived: sum of 2 quarters · filed 2025-03-24 | $34.11M derived: sum of 3 quarters · filed 2025-03-24 | $44.39M 10-K · filed 2025-03-24 | |||||
| 2023-09-30 | $11.61M 10-Q · filed 2024-11-18 | $617.00K 10-Q · filed 2023-11-14 | $21.93M derived: sum of 2 quarters · filed 2024-11-18 | $32.21M 10-Q · filed 2024-11-18 | $7.88M 10-Q · filed 2023-11-14 | $48.59M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2023-06-30 | $10.32M 10-Q · filed 2024-08-09 | -$426.00K 10-Q · filed 2023-08-10 | $20.60M 10-Q · filed 2024-08-09 | $7.26M 10-Q · filed 2023-08-10 | $36.98M derived: sum of 3 quarters · filed 2024-08-09 | $46.45M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $10.28M 10-Q · filed 2024-05-10 | $7.69M 10-Q · filed 2023-05-08 | $26.66M derived: sum of 2 quarters · filed 2024-05-10 | $36.13M derived: sum of 3 quarters · filed 2024-05-10 | $47.09M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | $16.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $25.85M derived: sum of 2 quarters · filed 2024-03-18 | $36.80M derived: sum of 3 quarters · filed 2024-03-18 | $47.51M 10-K · filed 2024-03-18 | $41.13M 10-K · filed 2023-03-20 | ||||
| 2022-09-30 | $9.47M 10-Q · filed 2023-11-14 | $20.43M derived: sum of 2 quarters · filed 2023-11-14 | $31.13M 10-Q · filed 2023-11-14 | $40.89M derived: sum of 4 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | $10.96M 10-Q · filed 2023-08-10 | $21.66M 10-Q · filed 2023-08-10 | $31.42M derived: sum of 3 quarters · filed 2023-08-10 | $41.31M derived: sum of 4 quarters · filed 2023-08-10 | |||||
| 2022-03-31 | $10.70M 10-Q · filed 2023-05-08 | $20.46M derived: sum of 2 quarters · filed 2023-05-08 | $30.36M derived: sum of 3 quarters · filed 2023-05-08 | $40.18M derived: sum of 4 quarters · filed 2023-05-08 | |||||
| 2021-12-31 | $9.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $19.66M derived: sum of 2 quarters · filed 2023-03-20 | $29.48M derived: sum of 3 quarters · filed 2023-03-20 | $39.16M 10-K · filed 2023-03-20 | |||||
| 2021-09-30 | $9.90M 10-Q · filed 2022-11-14 | $19.72M derived: sum of 2 quarters · filed 2022-11-14 | $29.40M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $9.82M 10-Q · filed 2022-08-09 | $19.51M 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | $9.71M 10-Q · filed 2022-05-09 | ||||||||
| 2020-09-30 | $6.22M 10-Q · filed 2021-11-04 | $11.06M derived: sum of 2 quarters · filed 2021-11-04 | $16.56M 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | $4.84M 10-Q · filed 2021-08-05 | $10.34M 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | $5.50M 10-Q · filed 2021-05-12 | ||||||||
| 2019-03-31 | $104.00K 10-Q · filed 2019-05-07 | $2.68M derived: sum of 2 quarters · filed 2019-05-07 | $13.39M derived: sum of 3 quarters · filed 2019-05-07 | $31.39M derived: sum of 4 quarters · filed 2019-05-07 | |||||
| 2018-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $13.29M derived: sum of 2 quarters · filed 2019-03-07 | $31.28M derived: sum of 3 quarters · filed 2019-03-07 | $41.79M 10-K · filed 2019-03-07 | |||||
| 2018-09-30 | $10.71M 10-Q · filed 2018-11-07 | $28.71M derived: sum of 2 quarters · filed 2018-11-07 | $39.22M 10-Q · filed 2018-11-07 | $50.78M derived: sum of 4 quarters · filed 2019-05-07 | |||||
| 2018-06-30 | $18.00M 10-Q · filed 2018-08-08 | $28.50M 10-Q · filed 2018-08-08 | $40.06M derived: sum of 3 quarters · filed 2019-05-07 | $48.52M derived: sum of 4 quarters · filed 2019-05-07 | |||||
| 2018-03-31 | $10.51M 10-Q · filed 2019-05-07 | $22.07M derived: sum of 2 quarters · filed 2019-05-07 | $30.52M derived: sum of 3 quarters · filed 2019-05-07 | $41.00M derived: sum of 4 quarters · filed 2019-05-07 | |||||
| 2017-12-31 | $11.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $20.02M derived: sum of 2 quarters · filed 2019-03-07 | $30.49M derived: sum of 3 quarters · filed 2019-03-07 | $36.27M 10-K · filed 2019-03-07 | |||||
| 2017-09-30 | $8.46M 10-Q · filed 2018-11-07 | $18.93M derived: sum of 2 quarters · filed 2018-11-07 | $24.71M 10-Q · filed 2018-11-07 | $32.84M derived: sum of 4 quarters · filed 2019-03-07 | |||||
| 2017-06-30 | $10.47M 10-Q · filed 2018-08-08 | $16.25M 10-Q · filed 2018-08-08 | $24.38M derived: sum of 3 quarters · filed 2019-03-07 | $30.52M derived: sum of 4 quarters · filed 2019-03-07 | |||||
| 2017-03-31 | $5.78M 10-Q · filed 2018-05-08 | $13.91M derived: sum of 2 quarters · filed 2019-03-07 | $20.04M derived: sum of 3 quarters · filed 2019-03-07 | $29.28M derived: sum of 4 quarters · filed 2019-03-07 | |||||
| 2016-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $14.27M derived: sum of 2 quarters · filed 2019-03-07 | $23.50M derived: sum of 3 quarters · filed 2019-03-07 | $28.38M 10-K · filed 2019-03-07 | |||||
| 2016-09-30 | $6.13M 10-Q · filed 2017-11-08 | $15.37M derived: sum of 2 quarters · filed 2017-11-08 | $20.25M 10-Q · filed 2017-11-08 | $24.18M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-06-30 | $9.23M 10-Q · filed 2017-08-08 | $14.12M 10-Q · filed 2017-08-08 | $18.04M derived: sum of 3 quarters · filed 2018-03-12 | $21.73M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-03-31 | $4.88M 10-Q · filed 2017-05-09 | $8.81M derived: sum of 2 quarters · filed 2018-03-12 | $12.49M derived: sum of 3 quarters · filed 2018-03-12 | $16.11M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | $3.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $7.61M derived: sum of 2 quarters · filed 2018-03-12 | $11.23M derived: sum of 3 quarters · filed 2018-03-12 | $15.80M 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $3.69M 10-Q · filed 2016-11-09 | $7.31M derived: sum of 2 quarters · filed 2016-11-09 | $11.87M 10-Q · filed 2016-11-09 | $18.20M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-06-30 | $3.62M 10-Q · filed 2016-08-04 | $8.19M 10-Q · filed 2016-08-04 | $14.51M derived: sum of 3 quarters · filed 2017-03-09 | $19.83M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-03-31 | $4.57M 10-Q · filed 2016-05-10 | $10.89M derived: sum of 2 quarters · filed 2017-03-09 | $16.21M derived: sum of 3 quarters · filed 2017-03-09 | $20.77M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2014-12-31 | $6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $11.65M derived: sum of 2 quarters · filed 2017-03-09 | $16.20M derived: sum of 3 quarters · filed 2017-03-09 | $18.08M 10-K · filed 2017-03-09 | $18.08M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | $5.32M 10-Q · filed 2015-11-10 | $5.32M 10-Q · filed 2014-11-04 | $9.87M derived: sum of 2 quarters · filed 2015-11-10 | $11.75M 10-Q · filed 2015-11-10 | $11.75M 10-Q · filed 2014-11-04 | $14.51M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-06-30 | $4.55M 10-Q · filed 2015-08-06 | $6.43M 10-Q · filed 2015-08-06 | $6.43M 10-Q · filed 2014-08-11 | $9.18M derived: sum of 3 quarters · filed 2016-03-14 | $12.21M derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-03-31 | $1.88M 10-Q · filed 2015-05-12 | $1.88M 10-Q · filed 2014-05-13 | $4.63M derived: sum of 2 quarters · filed 2016-03-14 | $7.66M derived: sum of 3 quarters · filed 2016-03-14 | $8.91M derived: sum of 4 quarters · filed 2016-03-14 | $43.79M 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $5.78M derived: sum of 2 quarters · filed 2016-03-14 | $7.03M derived: sum of 3 quarters · filed 2016-03-14 | $7.60M 10-K · filed 2016-03-14 | $7.60M 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | $3.03M 10-Q · filed 2014-11-04 | $4.27M derived: sum of 2 quarters · filed 2014-11-04 | $4.85M 10-Q · filed 2014-11-04 | ||||||
| 2013-06-30 | $1.25M 10-Q · filed 2014-08-11 | $1.82M 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | $572.97K 10-Q · filed 2014-05-13 | ||||||||
| 2012-12-31 | $6.05M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |